In vivo regulation of acetylcholine release via adenosine A1 receptor in rat cerebral cortex.
The roles of the endogenous adenosine on acetylcholine release via adenosine A1 receptor were investigated in rat cerebral cortex using brain microdialysis. Oral administration of KF15372 (8-dicyclopropylmethyl-1,3-dipropylxanthine), a novel selective adenosine A1 receptor antagonist, at doses of 1.25, 5, and 20 mg/kg, significantly increased the extracellular levels of acetylcholine in rat cerebral cortex. Selective A1 agonist N6-((R)-phenylisopropyl) adenosine (R-PIA) did not affect the extracellular level of acetylcholine by both oral (1.25 mg/kg) and intracortical administrations (0.3 microM) via dialysis probe. These results suggest that the extracellular level of acetylcholine is under tonic inhibitory control of endogenous adenosine via the A1 receptor.
Kurokawa
M
M
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co. Ltd., Shizuoka, Japan.
Shiozaki
S
S
Nonaka
H
H
Kase
H
H
Nakamura
J
J
Kuwana
Y
Y
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004563:Electrochemistry; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008297:Male; D017551:Microdialysis; D010660:Phenylisopropyladenosine / Q000494:pharmacology; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D051381:Rats; D017207:Rats, Sprague-Dawley; D011983:Receptors, Purinergic / Q000187:drug effects; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D014970:Xanthines / Q000494:pharmacology
D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011983:Receptors, Purinergic; D018047:Receptors, Purinergic P1; D014970:Xanthines; C067197:8-(dicyclopropylmethyl)-1,3-dipropylxanthine; D010660:Phenylisopropyladenosine; D000109:Acetylcholine